Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales up 15% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
3Q Revenues: $19.7 billion (+10%)
3Q Earnings: $3.8 billion (-12%)
YTD Revenues: $56.3 billion (+5%)
YTD Earnings: $12.0 billion (-6%)
Comments: Worldwide Pharmaceutical sales were $9.7 billion in the quarter, up 15%. Domestic sales increased 15% and international sales increased 16%. Remicade sales were $1.6 billion in the quarter, down 8%. Strong growth in new products include DARZALEX ($317 million, up 95%), for the treatment of patients with multiple myeloma and IMBRUVICA ($512 million, up 47%), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. Additional contributors to operational sales growth included STELARA ($1.1 billion, up 38%, a biologic for the treatment of a number of immune-mediated inflammatory diseases, XARELTO ($635 million, up 20%) an oral anticoagulant, ZYTIGA ($669 million, up 15%) an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer and INVEGA SUSTENNA/XEPLION/TRINZA ($643 million, up 16%), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters